

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Renninger Robert</u> _____ (Last) (First) (Middle) C/O ATHIRA PHARMA, INC. 18706 NORTH CREEK PARKWAY, SUITE 104 _____ (Street) BOTHELL WA 98011 _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 10/01/2024	3. Issuer Name and Ticker or Trading Symbol <u>Athira Pharma, Inc. [ ATHA ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ VP of Finance	5. If Amendment, Date of Original Filed (Month/Day/Year) _____ 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	76,595	D	

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (Right to Buy)	(1)	09/16/2030	Common Stock	18,915	17	D	
Stock Option (Right to Buy)	(2)	11/07/2030	Common Stock	1,085	22.22	D	
Stock Option (Right to Buy)	(3)	02/17/2031	Common Stock	10,000	21.15	D	
Stock Option (Right to Buy)	(4)	11/30/2031	Common Stock	13,000	12.38	D	
Stock Option (Right to Buy)	(5)	01/17/2032	Common Stock	40,600	10.64	D	
Stock Option (Right to Buy)	(6)	01/18/2033	Common Stock	56,750	3.37	D	
Stock Option (Right to Buy)	(7)	02/13/2034	Common Stock	74,154	3.26	D	

**Explanation of Responses:**

- One-fourth of the shares subject to the option vested on July 6, 2021 and one-fourth of the shares subject to the option vest on each year thereafter.
- One-fourth of the shares subject to the option vested on July 6, 2021 and one-fourth of the shares subject to the option vest on each year thereafter.
- One-fourth of the shares subject to the option vested on January 8, 2022 and one-fourth of the shares subject to the option vest on each year thereafter.
- One-fourth of the shares subject to the option vested on December 1, 2022 and one-fourth of the shares subject to the option vest on each year thereafter.
- One forty-eighth (1/48th) of the shares subject to the option vested on February 18, 2022 and one forty-eighth of the shares subject to the option will vest each month thereafter.
- One thirty-sixth (1/36th) of the shares subject to the option vested on February 19, 2023 and one thirty-sixth of the shares subject to the option vest each month thereafter.
- One forty-eighth (1/48th) of the shares subject to the option vested on March 14, 2024 and one forty-eighth of the shares subject to the option will vest each month thereafter.

**Remarks:**

Power of Attorney enclosed

s/ Mark Worthington,  
Attorney-in-Fact for  
Robert Renninger

10/03/2024

\*\* Signature of Reporting Person

Date

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**

## POWER OF ATTORNEY

The undersigned, as a Section 16 reporting person of Athira Pharma, Inc. (the "Company"), hereby constitutes and appoints Mark Worthington, Vieng Keophilavanh, Barbara Mery and each of the responsible attorneys and paralegals of Wilson Sonsini Goodrich & Rosati, Professional Corporation, the undersigned's true and lawful attorney-in-fact to:

1. complete and execute Forms ID, Update Passphrase Acknowledgment, 3, 4, and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his or her discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and
2. do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorney-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms ID, Update Passphrase Acknowledgment, 3, 4 and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of September 16, 2024.

Signature: /s/ Robert Renninger